Sit Less, Interact and Move More (SLIMM) 2 Study
NCT05173714 on ClinicalTrials.gov · last registry update 2026-07-27
Recruiting now, toward 156 participants. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 December 2021 — 4 years so far. semaglutide is already approved in the US for chronic kidney disease and obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Srinvasan Beddhu
- Sponsor type
- Other
- Enrollment
- 156
- Started
- 2021-12-01
- Primary completion
- 2026-12-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization
Conditions studied
Chronic Kidney Diseases · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.